Irbesartan is named as an intervention in 3 current clinical trials in our China, UK and USA registers. None are recruiting at the moment. The most common phase is Phase 2. The sponsor with the most trials is Travere Therapeutics, Inc (1). The most-studied condition is Immunoglobulin A Nephropathy.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
A Study of the Effect and Safety of HS-10390 in the Treatment of Patients with Primary IgA Nephropathy
NCT06635772 · ClinicalTrials.gov ↗ · Immunoglobulin a Nephropathy
|
Phase 2 | Not yet open | Hansoh BioMedical R&D Company | China |
|
A Study of the Effect and Safety of HS-10390 in the Treatment of Participants With Chronic Kidney Disease
NCT07555054 · ClinicalTrials.gov ↗ · Chronic Kidney Disease
|
Phase 2 | Not yet open | Jiangsu Hansoh Pharmaceutical Co., Ltd. | China |
|
A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA Nephropathy
NCT03762850 · ClinicalTrials.gov ↗ · Immunoglobulin A Nephropathy
|
Phase 3 | Active, closed | Travere Therapeutics, Inc. | UK, USA |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
The same active substance in our other registers, matched by its exact name. Each entry links to the register record it comes from.
30 single-substance products containing Irbesartan on the HPRA medicines list.
No entry for Irbesartan in the EMA, FDA or German BfArM shortage lists we track.
| Lead sponsor | Trials |
|---|---|
| Travere Therapeutics, Inc. | 1 |
| Jiangsu Hansoh Pharmaceutical Co., Ltd. | 1 |
| Hansoh BioMedical R&D Company | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 2 | 0 |
| Clinical trials in UK | 1 | 0 |
| Clinical trials in USA | 1 | 0 |
A trial with sites in more than one country appears in each of those registers.
3 current trials in our China, UK and USA registers name Irbesartan as a drug or biological intervention, as of the registry sync on 25 September 2026. Completed and withdrawn studies are not counted.
Not at the moment. None of the 3 trials in our registers is recruiting; they are active but closed to enrolment, not yet open, or enrolling by invitation. Only the study team can confirm whether a patient is eligible.
Travere Therapeutics, Inc (1), Jiangsu Hansoh Pharmaceutical Co., Ltd (1) and Hansoh BioMedical R&D Company (1). The number in brackets is how many trials each organisation leads.
Yes. The HPRA medicines list includes 30 single-substance products containing Irbesartan, for example Irbesartan Clonmel 150 mg film-coated tablets (Clonmel Healthcare Ltd). A licence does not mean a product is currently marketed or reimbursed; see each product's record.
Not in the lists we track: Irbesartan has no entry in the EMA, FDA or German BfArM shortage registers as of their latest sync.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Irbesartan works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Irbesartan works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Irbesartan (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 25 Sep 2026.